We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 126% below its sector, cheaper than its peers on earnings.
Xiangxue Pharmaceutical Co., Ltd. is actively involved in the full pharmaceutical lifecycle within China, from scientific research and product development to sourcing, production, and market distribution. The company's product portfolio notably includes its branded Xiangxue antivirotic oral liquids. Beyond these pharmaceutical offerings, it also provides a variety of healthcare supplements and comprehensive wellness solutions, such as specialized food and beverage items. Xiangxue Pharmaceutical has forged a strategic alliance with 111, Inc., with the aim of advancing an "Internet + Medicine" framework tailored for China's traditional Chinese medicine industry. The firm was established in 1997 and its main operations are based in Guangzhou, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300147.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
